DoD ALSRP Therapeutic Idea Grant: Advancing Early-Stage ALS Treatment Discovery

Applicants seeking support for the development of products beyond drug or treatment discovery should consider the FY17 ALSRP Therapeutic Development Award (Funding Opportunity Number: W81XWH-17-ALSRP-TDA), which supports advanced preclinical development activities (http://cdmrp.army.mil/funding/alsrp).
Innovation and impact are important aspects of the Therapeutic Idea Award. Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. Research must also have the potential for a major impact and accelerate progress toward treatment for ALS. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, ALS, even if clinical impact is not an immediate outcome. Presentation of preliminary data is not consistent with the intent of the Therapeutic Idea Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data, but on the innovative idea and the potential impact it will provide.

The Therapeutic Idea Award encourages applications that include meaningful and productive collaborations between investigators. As appropriate, applicants are encouraged to collaborate with industry partners and/or established ALS researchers.